Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
IF: 2.9 5-Year IF: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Print: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volume 37, 2020 Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2020029699
Forthcoming Article

Current Development of Oral Taxane Formulations: A Review

Nusrat Chowdhury
Xavier University of Louisiana
Mandip Singh
Florida Agricultural and Mechanical University

ABSTRACT

In this review, we describes the advances in oral drug delivery approaches for taxanes for successful therapeutic outcome. Taxanes (Paclitaxel and Docetaxel) have unwanted pharmacokinetic (PK) profiles when they are given in their current dosage forms. Taxanes have low bioavailability, are extensively metabolism by the CYP3A and have high affinity for p- glycoprotein. Regardless of all the dosage schedules, the overall DTX or PTX dose that a patient can tolerate at a given interval remains similar. Currently, there are no oral taxane nano-formulations commercially available to us and there remains several challenges which needs to be overcome. Nano-based formulations may offer prominent solutions when it come to the safety and effectiveness of the taxane delivery. Thus further research is necessary before such taxane nano-formulations can be made available to us both clinically and commercially.